Document is current
Any future updates will be listed below
-
Authors
Hafner, Michael
Eckardt, Franziska
Siedlecki, Jakob
Schworm, Benedikt
Herold, Tina R.
Asani, Ben
Priglinger, Siegfried G.
Schiefelbein, Johannes B.
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 20 February 2025
Accepted: 4 April 2025
First Online: 11 April 2025
Declarations
:
: Ethics approval was granted by the Institutional Review Board of the Faculty of Medicine, LMU Munich, study ID: 20–0382, and the study followed the principles of the Declaration of Helsinki of 1964 and its later amendments. Data extraction was carried out completely anonymously, with no reference to patient names or IDs. Informed consent was obtained in accordance with institutional guidelines.
: B.A. has received speaker honoraria and research support from Novartis and research support from Alcon. FE has received speaker honoraria from Novartis. J.S. has received honoraria and served on advisory boards for Novartis, AbbVie/Pharm-Allergan, Bayer, Roche, Apellis, and Hexal. Additionally, he has received honoraria from Heidelberg Engineering. B.S. has received speaker honoraria from Novartis. T.R.H. has received honoraria for Novartis, AbbVie/Pharm-Allergan, Bayer, Roche, Novonordisk and served on advisory boards for Bayer and Roche. S.G.P. has received advisory board honoraria from Novartis, Pharm-Allergan, Bayer, and Alcon. He has also received consulting or advisory board honoraria from Zeiss, BVI, Roche and Bausch & Lomb. J.B.S. has received speaker honoraria and research support from Novartis. M.H. declares no financial disclosures. All authors affirm that these conflicts of interest do not affect or influence the design, conduct, or reporting of this study.
